A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 804-810

  Steele, Nicola L ^a,b   Plumb, Jane A ^b   Vidal, Laura ^c   Tjrørnelund, Jette ^d   Knoblauch, Poul ^d   Rasmussen, Annie ^d   Chean, Eng Ooi ^e   Buhl Jensen, Peter ^d   Brown, Robert ^b   Evans, T R Jeffry ^a,b   DeBono, Johann S ^c  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d BioAlliance Pharma   (France)

^e CURAGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; BELINOSTAT; CASPASE; CYTOKERATIN 18; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACETYLATION; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSGEUSIA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INJECTION SITE THROMBOSIS; KIDNEY CANCER; LETHARGY; LOWER ESOPHAGUS SPHINCTER; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; OVARY CANCER; PERITONEUM PSEUDOMYXOMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; SARCOMA; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TACHYCARDIA; THYMOMA; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INFUSIONS, INTRAVENOUS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION;

EID: 38949146399     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1786     Document Type: Article

References (16)

1. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
2. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5.
3. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5:245-53.
4. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
5. Chan HM, Krstic-Demonacos M, Smith L, et al. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 2001;3:667-74.
6. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-8.
7. Therasse P. Evaluation of response. new and standard criteria. Ann Oncol 2002;13 Suppl 4:127-9.
8. Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
9. Takada M, Kataoka A, Toi M, et al. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol 2004;25:397-405.
10. Sinha R, Moliffe R, Scurr M, et al. A phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin or paclitaxel or both in patietns with advanced solid tumors. Proc Am Soc Clin Oncol 2007;25:18s.
11. Northfelt DW, Marschke RF, Bonnem et al. A phase Ib/II study of PXD101 alone and in combination with 5-FU in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2007;25:18s.
12. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2002;8:718-28.
13. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88.
14. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001;7:3047-55.
15. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-22.
16. Sosman JA, Aronson FR, Sznol M, et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res 1997;3:39-46.